Achieve Life Sciences

77 articles about Achieve Life Sciences

• Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

  9/11/2023

  Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced that Phase 2 ORCA-V1 trial results will be presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting, being held in London September 11–13, 2023.

• Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

  9/7/2023

  Achieve Life Sciences, Inc. today announced that John Bencich, CEO of Achieve, will be participating at three upcoming conferences.

• Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast

  8/1/2023

  Achieve Life Sciences, Inc. today announced it will report its second quarter 2023 financial results on Monday, August 14, 2023, and host a conference call and webcast on Tuesday, August 15, 2023, at 8:30 AM EDT.

• Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting

  7/18/2023

  Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced participation on a panel during the 2023 American Society of Pharmacognosy (ASP) Annual Meeting.

• Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

  7/11/2023

  Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced the publication in JAMA of the results from the Phase 3 ORCA-2 randomized placebo-controlled clinical trial of cytisinicline as a treatment for smoking cessation, the first large trial of this medication conducted in the United States.

• Achieve Life Sciences Announces Participation at Upcoming June 2023 Investor Conferences

  6/6/2023

  Achieve Life Sciences, Inc. announced that John Bencich, CEO of Achieve, will be presenting at the LD Micro Invitational XIII in Los Angeles and the Maxim Virtual Healthcare Conference.

• Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering

  5/25/2023

  Achieve Life Sciences, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 3,000,000 shares of common stock at a price of $5.50 per share in a registered direct offering.

• Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

  5/23/2023

  Achieve Life Sciences, Inc., a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced positive topline results from the Phase 3 ORCA-3 trial of cytisinicline.

• Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023

  4/26/2023

  Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced it will report its first quarter 2023 financial results and provide an update on the cytisinicline development program on Tuesday, May 9, 2023 at 4:30 PM EDT.

• Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline

  4/20/2023

  Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today reported positive topline results from its Phase 2 ORCA-V1 trial.

• Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference

  4/14/2023

  Achieve Life Sciences, Inc. (Nasdaq: ACHV) today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2023 Conference being held at the Seattle Convention Center April 25-26, 2023.

• Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking CessationTopline Data Expected in 2Q 2023

  3/29/2023

  Achieve Life Sciences, Inc. today announced that the last study follow-up visit for the last subject enrolled in the Phase 3 ORCA-3 trial has occurred.

• Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette CessationTopline Data Expected in 2Q 2023

  3/8/2023

  Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the last study follow-up visit for the last subject enrolled in the Phase 2 ORCA-V1 trial has occurred.

• Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

  3/3/2023

  Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced data from the Phase 3 ORCA-2 trial will be presented at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, being held in San Antonio, TX, March 1-4, 2023.

• Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023

  3/2/2023

  Achieve Life Sciences, Inc. announced it will report its fourth quarter and year-end 2022 financial results and provide an update on the cytisinicline development program on Thursday, March 16, 2023 at 4:30 PM EDT.

• Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette CessationTopline Data Expected in 2Q 2023

  2/7/2023

  Achieve Life Sciences, Inc. today announced that the final subject of the Company’s Phase 2 ORCA-V1 trial has completed treatment in the study.

• Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference

  2/2/2023

  Achieve Life Sciences, Inc. today announced it will participate in one-on-one meetings during the 2023 SVB Securities Global Biopharma Conference.

• Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

  1/9/2023

  Achieve Life Sciences, Inc. today announced that the final subject of the Company’s Phase 3 ORCA-3 trial has completed treatment in the study.

• Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation

  12/21/2022

  Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,459,328 covering the mesylate salt formulation of cytisinicline and the process for its development.

• Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial

  9/27/2022

  Achieve Life Sciences, Inc. today announced that target enrollment of 750 subjects has been reached in the Phase 3 ORCA-3 trial.